The prognostic inconsistency of mTOR in RCC might be due to RCC specimens (remarkable heterogeneity, varied sample size and divergence of clinicopathological backgrounds), mutation and amplification of PI3K/AKT/mTOR pathway members, or overexpression of the components of mTORC1 and mTORC2 (Fan et al., 2020; Hua et al., 2019). The gene discussed is MTOR; the disease is renal cell carcinoma.